CoChat

Changes in serum receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

Buxton, Eric C., Yao, Wei, Lane, Nancy E. · 2004 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Changes in biochemical markers of bone turnover following intermittent injections of human (h)PTH (1-34) suggest that bone formation is initially favored over bone resorption. hPTH (1-34) is also known to influence osteoclast maturation and activity through modulation of osteoblast-derived cytokines, such as receptor activator of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), IL-6, and IL-6 soluble receptor (IL-6sR). In this experiment, we investigated the changes in serum levels of soluble RANKL (sRANKL), OPG, IL-6, and IL-6sR in patients with glucocorticoid-induced osteoporosis treated with hPTH (1-34). Fifty-one postmenopausal women with glucocorticoid-induced osteoporosis were randomized to receive 12 months of 400 U hPTH (1-34) ( approximately 40 microg) daily and standard hormone replacement therapy, or hormone replacement therapy alone. Serum levels of sRANKL, OPG, IL-6, and IL-6sR were measured at baseline, 1 month, and every 3 months thereafter for a total of 24 months. hPTH (1-34) caused a rapid and significant increase in sRANKL within 1 month, and the levels remained elevated throughout the duration of therapy. IL-6 and IL-6sR increased significantly within 1 month, but returned to baseline levels more rapidly. In contrast, OPG was mildly suppressed beginning 6 months after hPTH therapy. These data support the hypothesis that hPTH (1-34) initially stimulates osteoblast maturation and function, which in turn leads to osteoclast activation and a gradual rebalancing of bone formation and resorption.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2003-032066

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 79

Metadata

Authors
Buxton, E. C., Yao, W., & Lane, N. E.
Affiliations
University of California, San Francisco (US)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2004-07-01
Volume
89
Issue
7
Pages
3332-3336
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2042509724
Cited by
79
References
29
Citations by year
2026: 1 · 2025: 1 · 2023: 1 · 2022: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 1 · 2014: 1 · 2013: 5 · 2012: 3
FWCI
3.43
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01dk046661-05)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK 46661-07)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24AR048841, AR048841-01)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
Keywords
glucocorticoid-induced osteoporosis, human parathyroid hormone (1-34), RANKL, osteoprotegerin, interleukin-6, bone turnover markers, postmenopausal women, hormone replacement therapy, osteoclast activation, osteoblast maturation, bone formation and resorption
MeSH terms
Aged, Aged, 80 and over, Carrier Proteins, Female, Follow-Up Studies, Glucocorticoids, Glycoproteins, Humans, Membrane Glycoproteins, Middle Aged, Osteoporosis, Parathyroid Hormone, Peptide Fragments, Solubility, Time Factors, Interleukin-6, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Receptors, Interleukin-6, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.